<DOC>
	<DOCNO>NCT01544881</DOCNO>
	<brief_summary>This Open-label , randomize study Type 1 diabetic look exposure response ( PK/PD ) TI use GEN2C Inhaler versus rapid act analog .</brief_summary>
	<brief_title>Comparison Technosphere Insulin Inhalation Powder &amp; Subcutaneous Rapid-Acting Analog Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>Subjects Type 1 diabetes randomize either one dose TI inhale use Gen2C device , one dose subcutaneously inject Rapid Acting Analog ( RAA ) cross . Crossover Sequences : Sequence # 1 : Period 1 - one 20 U cartridge TI ; Period 2 - 8 U RAA Sequence # 2 : Period 1 - 8 U RAA ; Period 2 - one 20 U cartridge TI An euglycemic clamp procedure perform dose visit . The purpose study characterize pharmacokinetics ( PK ) one dose TI Inhalation Powder use Gen2C inhaler compare one dose subcutaneous RAA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Men woman age 18 60 year One daily sc insulin injection insulin type insulin pump use Body mass index ( BMI ) = 30 kg/m2 Pulmonary function test ( PFTs ) conduct Visit 1 : FEV1 ≥ 80 % Third National Health Nutrition Examination Survey ( NHANES III ) predict FVC ≥ 80 % Third National Health Nutrition Examination Survey ( NHANES III ) predict Diagnosis type 1 diabetes least 12 month Good venous access blood draw Written inform consent provide No smoke previous 6 month ( include cigarette , cigar , pipe ) negative urine cotinine testing ( &lt; 100 ng/mL ) Cpeptide &lt; 0.3 ng/mL Hemoglobin A1c ( HbA1c ) = 10.0 % Total daily insulin requirement = 1.4 U/kg body weight Serum creatinine = 2.0 mg/dL men &gt; 1.8 mg/dL woman Blood donation 500 mL within previous 56 day Current treatment pramlintide acetate exenatide Unstable diabetes control evidence severe complication diabetes ( ie , autonomic neuropathy ) History chronic obstructive pulmonary disease ( COPD ) asthma , clinically important pulmonary disease confirm pulmonary function test radiologic finding Upper respiratory tract infection within 8 week screen History coronary artery disease , peripheral vascular disease , congestive heart failure Allergy study drug , food , study material ( eg , peanut , soy product ) Clinically significant active chronic illness History drug alcohol abuse Positive urine drug screen Clinically significant screening ECG , physical examination , laboratory test , vital sign abnormality Exposure investigational drug device within 30 day treatment within 90 day treatment drug know modify glucose metabolism ( except metformin ) History malignancy within 5 year screen ( basal cell carcinoma ) History human immunodeficiency virus ( HIV ) infection hepatitis B C Women pregnant , lactating , plan become pregnant clinical study period Women childbearing potential ( define premenopausal surgically sterilize postmenopausal few 2 year ) practice adequate birth control . Adequate birth control define use oral , percutaneous , transdermal contraceptive ; condom diaphragms ( double barrier ) spermicide ; intrauterine device . Postmenopausal purpose clinical study include experience amenorrhea 2 year surgically sterile Inability , opinion PI designee , adequately inhale TI Inhalation Powder Any subject , opinion PI designee , appear qualified study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Insulin</keyword>
</DOC>